Featured Content
Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma
In this webcast, expert faculty discuss best practices in treating patients with relapsed/refractory multiple myeloma and discuss the patient's perspective on treatment options. Learners will also get a look ahead at emerging therapeutic strategies and clinical trials...
Overview of Key Early-phase CAR T-cell Therapy Studies in Relapsed or Refractory Multiple Myeloma
In this article, we look at some of the early-phase clinical trials, where chimeric antigen receptor (CAR) T-cell therapy has been targeted to the B-cell maturation antigen (BCMA) in patients with relapsed or refractory MM (RRMM). The anti-BCMA CAR T-cell...
What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?
CAR T-cell structure CARs are typically composed of four regions: (1) an extracellular antigen-binding domain; (2) a hinge or spacer peptide; (3) a transmembrane domain that anchors the CAR to the cell membrane; and (4) one or more intracellular signalling domains...
Myeloma News
Myeloma-bone marrow adipocyte axis in tumour survival and treatment response
Source: Myeloma : nature.com subject feeds Read More
Top Myeloma Journal Articles for the Week of June 14, 2021
Here are the top 10 journal articles from the week of June 14, 2021 as selected by the MYELOMA360 staff. Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple...
Off-the-shelf immune drug shows promise in aggressive multiple myeloma
Source: Multiple Myeloma News -- ScienceDaily A subcutaneous injection of the immune-boosting drug teclistamab was found to be safe and elicit responses in a majority of patients with relapsed or refractory multiple myeloma. Read More
Treating COVID-19 in a patient with multiple myeloma
Source: Multiple Myeloma News -- ScienceDaily A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may be an effective COVID-19 treatment for very ill patients who also have multiple myeloma and other blood cancers. The report...
New technology helps in hunt for new cancer drug combinations
Source: Multiple Myeloma News -- ScienceDaily A revolutionary new technology has been applied to reveal the inner workings of individual cancer cells - potentially identifying more effective treatment combinations for people with cancer. Read More
Lenalidomide may delay onset of myeloma-related bone, organ damage
Source: Multiple Myeloma News -- ScienceDaily The largest randomized trial in asymptomatic patients with smoldering multiple myeloma suggests that lenalidomide, a cancer drug, may delay the onset of bone and other myeloma-related organ damage. Read More
Unprecedented therapy found effective for blood cancer patients with no treatment options
Source: Multiple Myeloma News -- ScienceDaily Researchers have found a new type of therapy to be effective for patients with a particular type of bone marrow cancer that is resistant to several standard therapies. Read More
New epigenetic regulatory mechanisms involved in multiple myeloma growth
Source: Multiple Myeloma News -- ScienceDaily An international team of researchers has analyzed the function of the histone demethylase KDM5A in multiple myeloma, one of the three major hematological cancers, and clarified the mechanism by which it promotes myeloma...
Personalized cancer vaccine deemed safe, shows potential benefit against cancer
Source: Multiple Myeloma News -- ScienceDaily A personalized cancer vaccine raised no safety concerns and showed potential benefit in patients with different cancers, including lung and bladder, that have a high risk of recurrence, according to results from an...
New CAR T-Cell therapy extends remission in heavily relapsed multiple myeloma patients
Source: Multiple Myeloma News -- ScienceDaily A new type of CAR T-cell therapy more than triples the expected length of remission for multiple myeloma patients who have relapsed several times, according to an international clinical trial. Read More
Recent Publications
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
Lancet Oncol. 2021 Jun;22(6):801-812. doi: 10.1016/S1470-2045(21)00128-5.ABSTRACTBACKGROUND: In a phase 1b study, intravenous daratumumab plus pomalidomide and dexamethasone induced a very good partial response or better rate of 42% and was well tolerated in patients...
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma.
The anti-B-cell maturation antigen BiTE molecule AMG 420 was assessed in patients with relapsed/refractory multiple myeloma.In this first-in-human study, up to 10 cycles of AMG 420 were given (4-week infusions/6-week [...]
Implementation of the International Myeloma Working Group reccomendations on renal impairment in multiple myeloma patients in routine clinical practice.
Click here to read the full article @ Annals of oncology : official journal of the European Society for Medical Oncology
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.
The combination of lenalidomide, bortezomib, and dexamethasone (RVD) is a highly effective and convenient induction regimen for both transplantation-eligible and -ineligible patients with myeloma. Here, we present the largest cohort [...]
How We Approach Smoldering Multiple Myeloma.
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management [...]
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of [...]
Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma.
18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) is currently the standard technique to define minimal residual disease (MRD) status outside the bone marrow (BM) in patients with multiple myeloma [...]
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial.
Maintenance therapy prolongs progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM) not undergoing autologous stem cell transplantation (ASCT) but has generally been limited to immunomodulatory agents. Other [...]
Twitter Discussions
[Action required] Your RSS.app Trial has Expired – Mon Jun 21 2021
Your trial has expired. Please update your subscription plan at rss.app. - (7M6LiAM1PoXxlmaI)
MM_Hub: CONGRESS|#EHA2021|@ThierryFacon, Lille University Hospital, presented poster on Phase3 IKEMA trial. It was identified that addition of Isatuximab to carfilzomib & dexamethasone improved PFS & quality of response in elderly pts, with a manageable safety profile #mmsm #myeloma
CONGRESS|#EHA2021|@ThierryFacon, Lille University Hospital, presented poster on Phase3 IKEMA trial. It was identified that addition of Isatuximab to carfilzomib & dexamethasone improved PFS & quality of response in elderly pts, with a manageable safety profile...
VincentRK: The 12th Annual International Myeloma Working Group (IMWG) Summit starts next week. ~100 myeloma experts will participate virtually on new treatment guidelines & research projects. @IMFmyeloma @BrianDurieMD Dr. Munshi and Dr. Kumar will be honored. @DanaFarber @MayoClinic
The 12th Annual International Myeloma Working Group (IMWG) Summit starts next week. ~100 myeloma experts will participate virtually on new treatment guidelines & research projects. @IMFmyeloma @BrianDurieMD Dr. Munshi and Dr. Kumar will be honored. @DanaFarber...
MM_Hub: CONGRESS|#EHA2021|@nickbolli, Universita Degli Studi di Milano emphasized upon genotyping potential to diagnose MGUS/SMM, to identify progression determinants, to provide better classification& prognostication of MM. More research is needed for clinical translation #mmsm #myeloma
CONGRESS|#EHA2021|@nickbolli, Universita Degli Studi di Milano emphasized upon genotyping potential to diagnose MGUS/SMM, to identify progression determinants, to provide better classification& prognostication of MM. More research is needed for clinical...
MM_Hub: CONGRESS|#EHA2021| Paula Rodriguez- Otero, discussed currently cellular therapies for MM and highlighted future treatment possibilities #mmsm #myeloma @ClinicaNavarra
CONGRESS|#EHA2021| Paula Rodriguez- Otero, discussed currently cellular therapies for MM and highlighted future treatment possibilities #mmsm #myeloma @ClinicaNavarra pic.twitter.com/nYwSCcEOwG— Multiple Myeloma Hub (@MM_Hub) June 15, 2021
